PRL-3基因对胶质母细胞瘤替莫唑胺敏感性的影响

doi:10.20047/j.issn1673-7210.2023.11.03

Abstract
Figure/Table
References (24)
Related Citation (7)

Download: PDF (1998 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the expression of PRL-3 gene in glioblastoma and its effect on the sensitivity of Temozolomide in glioblastoma. Methods The expression of PRL-3 gene in glioblastoma and normal tissues was analyzed by the TCGA database, and postoperative tumor tissues of 15 patients with glioblastoma diagnosed and treated by the First Affiliated Hospital of Air Force Military Medical University (ten primary cases, five recurrent cases) were further selected, the expression of PRL-3 positive cells in primary and recurrent glioblastoma tissues was detected by immunohistochemistry. Human glioblastoma LN229 and temozolomid-resistant LN229/TMZ-R cell lines were selected to detect PRL-3 mRNA and protein expression by qRT-PCR and Western blot. LN229, SHG44, and U87 cell lines which was insensitive to Temozolomide were selected, and normal group, control group, no-load liposome group, PRL-3 overexpression group, and PRL-3 downregulation group were set, respectively. The PRL-3 mRNA expression of control group, no-load liposome group, PRL-3 overexpression group, and PRL-3 downregulation group were compared to verify the success of PRL-3 overexpression and downregulation. Then the normal group, PRL-3 overexpression group, and PRL-3 downregulation group were treated with Temozolomide(LN229 and SHG44 cell lines were treated with 100 μmol/L Temozolomide, U87 cell line were treated with 500 μmol/L Temozolomide), while the normal group was not treated, the cell activity was evaluated by CCK-8 method after 72 h. Results Database analysis showed that PRL-3 expression in primary glioblastoma was higher than that in normal tissues and increased with the increase of tumor grade (P＜0.05). The immunohistochemical scores of PRL-3 positive cells in recurrent glioblastoma tissues was higher than that in primary glioblastoma tissues (P＜0.05). The mRNA expression of PRL-3 in LN229/TMZ-R cell line was higher than that in LN229 cell line (P＜0.05), and PRL-3 protein was highly expressed in LN229/TMZ-R cell line. The PRL-3 mRNA in PRL-3 overexpression group was higher than that in normal group, and the PRL-3 downregulation group was lower than that in normal group (P＜0.05). In LN229, SHG44, and U87 cell lines, the cell activity of control group was lower than that of normal group, the cell activity of PRL-3 overexpression group was higher than that of control group, and the cell activity of PRL-3 downregulation group was lower than that of control group (P＜0.05). Conclusion The low expression of PRL-3 gene can enhance the sensitivity of glioblastoma to Temozolomide treatment, which is expected to be a beneficial target for synergistic chemotherapy with Temozolomide.

Key words： PRL-3 gene Glioblastoma Temozolomide Chemotherapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Yuqi1 WANG Yingwen2 JIA Bo3 GUO Qingdong3▲

Cite this article:

YANG Yuqi1 WANG Yingwen2 JIA Bo3 GUO Qingdong3▲. Effect of PRL-3 gene on sensitivity of Temozolomide in glioblastoma[J]. 中国医药导报, 2023, 20(11): 14-18.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.11.03 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I11/14

[1] Karlsson J，Luly KM，Tzeng SY，et al. Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies [J]. Adv Drug Deliv Rev，2021，179：113999.
[2] Fisher JP，Adamson DC. Current FDA-Approved Therapies for High-Grade Malignant Gliomas [J]. Biomedicines，2021， 9（3）：324.
[3] Yin D，Ogawa S，Kawamata N，et al. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme [J]. Oncogene，2013，32（9）：1155-1163.
[4] Yu S，Guryanova OA，Wenchao Z，et al. Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance [J]. Sci Transl Med，2018，10（443）：eaah6816.
[5] Huang B，Yu Z，Liang R. Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival [J]. BMC Neurol，2021，21（1）：424.
[6] Jiapaer S，Furuta T，Tanaka S，et al. Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma [J]. Neurol Med Chir（Tokyo），2018，58（10）：405-421.
[7] Zhang M，Wei Y，Liu Y，et al. Metastatic Phosphatase PRL-3 Induces Ovarian Cancer Stem Cell Sub-population through Phosphatase-Independent Deacetylation Modulations [J]. iScience，2020，23（1）：100766.
[8] Xu H，Zeng Y，Liu L，et al. PRL-3 improves colorectal cancer cell proliferation and invasion through IL-8 mediated glycolysis metabolism [J]. Int J Oncol，2017，51（4）：1271- 1279.
[9] Liu C，Zhong W，et al. A retrospective cohort study of clinical value of PRL-3 in stage Ⅲ human colorectal cancer [J]. Medicine（Baltimore），2021，100（17）：e25658.
[10] Chong PSY，Zhou J，Cheong LL，et al. LEO1 Is Regulated by PRL-3 and Mediates Its Oncogenic Properties in Acute Myelogenous Leukemia [J]. Cancer Res，2014，74（11）：3043- 3053.
[11] Yang Y，Lian S，Meng L，et al. Antibody array revealed PRL-3 affects protein phosphorylation and cytokine secretion [J]. PLoS One，2017，12（1）：e0169665.
[12] Zhou Q，Zhou Q，Liu Q，et al. PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK [J]. Theranostics，2020，10（22）：10345-10359.
[13] Nan M，Jintao G，Nannan L，et al. PRL-3 is a potential glioblastoma prognostic marker and promotes glioblastoma progression by enhancing MMP7 through the ERK and JNK pathways [J]. Theranostics，2018，8（6）：1527-1539.
[14] 康恩铭，章薇，章翔.甲基化状态风险分析对胶质母细胞瘤患者预后评价意义[J].中华神经外科疾病研究杂志，2018，17（1）：27-31.
[15] Upadhyay UM，Tyler B，Patta Y，et al. Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain [J]. Proc Natl Acad Sci U S A，2014，111（45）：16071-16076.
[16] Zimmerman MW，Homanics GE，Lazo JS. Targeted deletion of the metastasis-associated phosphatase Ptp4a3（PRL-3）suppresses murine colon cancer [J]. PLoS One，2013，8（3）：e58300.
[17] Xiong J，Li Z，Zhang Y，et al. PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K/Akt signaling pathway by regulating PTEN [J]. Oncol Rep，2016， 36（4）：1819-1828.
[18] Jiang Y，Liu XQ，Rajput A，et al. Phosphatase PRL-3 is a direct regulatory target of TGFβ in colon cancer metastasis [J]. Cancer Res，2011，71（1）：234-244.
[19] Guzińska-Ustymowicz K，Ki■luk J，Terlikowski SJ，et al. Expression of phosphatase of regenerating liver-3 （PRL-3） in endometrioid cancer and lymph nodes metastases [J]. Adv Med Sci，2013，58（2）：221-226.
[20] Dong Q，Ding X，Chang B，et al. PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma [J]. J Oral Pathol Med，2016， 45（2）：111-118.
[21] Andersen S，Richardsen E，Rakaee M，et al. Expression of phosphatase of regenerating liver（PRL）-3，is independently associated with biochemical failure，clinical failure and death in prostate cancer [J]. PLoS One，2017，12（11）：e0189000.
[22] Smith CN，Blackburn JS. PRL-3 promotes a positive feedback loop between STAT1/2-induced gene expression and glycolysis in multiple myeloma [J]. FEBS J，2021，288（23）：6674-6676.
[23] Bilici A，Ustaalioglu BBO，Yavuzer D，et al. Prognostic significance of high phosphatase of regenerating liver-3 expression in patients with gastric cancer who underwent curative gastrectomy [J]. Dig Dis Sci，2012，57（6）：1568-1575.
[24] Duciel L，Gomez LCM，Kondratova M，et al. The phosphatase PRL-3 is involved in key steps of cancer metastasis [J]. J Mol Biol，2019，431（17）：3056-3067.